Impact of Contextual-Level Social Determinants of Health on Newer Antidiabetic Drug Adoption in Patients with Type 2 Diabetes

Yujia Li, Hui Hu, Yi Zheng, William T. Donahoo, Yi Guo, Jie Xu, Wei‐Han Chen, Ning Liu, Elisabeth A. Shenkman, Jiang Bian, Jingchuan GuoInternational Journal of Environmental Research and Public Health 2023 · DOI

TL;DR

This study reveals that where you live significantly impacts your access to newer, more effective diabetes medications. Patients in neighborhoods with higher deprivation and more vacant properties are less likely to receive these beneficial drugs, highlighting a critical gap in equitable healthcare delivery.

What Problem Does This Paper Address?

Type 2 Diabetes (T2D) is a major health concern, with cardiovascular disease being a leading cause of death among T2D patients. Newer antidiabetic drugs (ADDs), specifically SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1a), have shown significant benefits, including reducing blood glucose and protecting against cardiovascular and kidney disease. Despite these advantages, their adoption in real-world patient populations is lower than expected, particularly among minority and socioeconomically disadvantaged groups. While individual-level factors are often considered, this paper investigates the crucial role of contextual-level social determinants of health (SDoH) – the broader social and built environment of a neighborhood – in influencing the uptake of these vital medications. Understanding these neighborhood-level factors is essential for addressing racial and ethnic disparities in diabetes care and developing targeted interventions.

Methods

The researchers employed a retrospective cohort study using electronic health records (EHR) from the OneFlorida+ network. They identified T2D patients who initiated a second-line ADD between 2015 and 2020. A key methodological innovation was the linkage of 81 contextual-level SDoH measures to individual patients based on their residential histories. These SDoH measures captured aspects of the social and built environment, such as food access, walkability, vacant land, socioeconomic status, social capital, and crime/safety.

To identify the most impactful SDoH, a two-phase statistical approach was used:

  • Phase 1 (Discovery and Replication): The data was split into two halves. Multivariable logistic regression models were built to assess the association between each SDoH and the initiation of newer ADDs, controlling for demographic and clinical factors. The Benjamin-Hochberg procedure was used to adjust for multiple comparisons. Variables significant in both the discovery and replication sets were retained. Highly correlated variables were removed to avoid multicollinearity.
  • Phase 2 (Validation): The significant SDoH identified in Phase 1 were included in a final multivariable logistic regression model, along with all demographic and clinical covariates, to estimate the effect sizes.

Datasets

The primary dataset used was the OneFlorida+ network, a large collection of electronic health records from over 19 million patients across Florida, Georgia, and Alabama. This dataset provided the patient-level demographic, clinical, and prescription information.

Contextual-level SDoH data were aggregated from various sources:

  • Food Access: USDA's Food Access Research Atlas.
  • Walkability: National Walkability Index (EPA).
  • Vacant Land: US Department of Housing and Urban Development (HUD) and US Postal Service administrative data.
  • Neighborhood Deprivation Index (NDI): American Community Survey (ACS) data.
  • Social Capital: Census Business Pattern data.
  • Crime and Safety: Uniform Crime Reporting Program (FBI).

No new benchmarks were introduced; the study focused on integrating existing SDoH data with EHR data.

Key Insights and Ideas

  • Neighborhood Matters, A Lot: The study powerfully demonstrates that the characteristics of a patient's neighborhood are not just background noise but actively influence their access to evidence-based diabetes treatments.
  • Deprivation and Vacancy as Barriers: The most significant contextual-level SDoH identified were the neighborhood deprivation index and the percentage of vacant addresses. This suggests that areas with higher socioeconomic disadvantage and physical disinvestment are associated with lower adoption of newer, beneficial diabetes medications.
  • Beyond Individual Factors: While racial and ethnic disparities were observed (Black patients were less likely to use newer ADDs), the study found no significant interaction between race/ethnicity and SDoH. This implies that while race is a factor, the neighborhood environment itself plays a direct, independent role in shaping treatment access, potentially exacerbating existing disparities.
  • Data-Driven Approach: The use of a large EHR network combined with spatiotemporally linked SDoH data provides a robust, data-driven approach to understanding these complex relationships.

Key Results

  • Significant SDoH: Two contextual-level SDoH were significantly associated with a lower likelihood of initiating newer ADDs:
  • Neighborhood Deprivation Index (NDI): An increase in NDI was associated with a lower likelihood of prescription (Odds Ratio [OR] 0.87, 95% Confidence Interval [CI] 0.81–0.94).
  • Percent of Vacant Addresses: Higher percentages of vacant addresses were also linked to a lower likelihood of prescription (OR 0.91, 95% CI 0.85–0.98).
  • Racial Disparities: In the overall cohort, Non-Hispanic Black individuals were less likely to use newer ADDs compared to Non-Hispanic White individuals (Adjusted OR [aOR] 0.82, 95% CI 0.76–0.88).
  • No Interaction: Importantly, the study found no significant interaction between race/ethnicity and the identified contextual-level SDoH on the use of newer ADDs.

Limitations and Future Work

The authors acknowledge several limitations:

  • Gestational Diabetes: The cohort included patients with gestational diabetes, potentially leading to misclassification if not diagnosed by physicians.
  • Model Complexity: The two-phase approach did not account for non-linear associations or potential interactions between SDoH. Future work could explore more complex models like generalized additive models or Bayesian kernel machine regression.
  • Exhaustiveness of SDoH: While 81 SDoH measures were included, the list is not exhaustive, and efforts to improve SDoH measurement are ongoing.
  • EHR Data Limitations: The study used EHR data, and while efforts were made to exclude prevalent users of second-line ADDs, this possibility cannot be entirely ruled out.
  • Generalizability: The study cohort was limited to patients within the OneFlorida+ network, potentially limiting generalizability to those receiving care outside this network.

Future work should focus on investigating the specific mechanisms underlying these associations and developing targeted interventions to address these neighborhood-level barriers to evidence-based diabetes care.

Summary updated

Abstract

Background: We aimed to investigate the association between contextual-level social determinants of health (SDoH) and the use of novel antidiabetic drugs (ADD), including sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1a) for patients with type 2 diabetes (T2D), and whether the association varies across racial and ethnic groups. Methods: Using electronic health records from the OneFlorida+ network, we assembled a cohort of T2D patients who initiated a second-line ADD in 2015–2020. A set of 81 contextual-level SDoH documenting social and built environment were spatiotemporally linked to individuals based on their residential histories. We assessed the association between the contextual-level SDoH and initiation of SGTL2i/GLP1a and determined their effects across racial groups, adjusting for clinical factors. Results: Of 28,874 individuals, 61% were women, and the mean age was 58 (±15) years. Two contextual-level SDoH factors identified as significantly associated with SGLT2i/GLP1a use were neighborhood deprivation index (odds ratio [OR] 0.87, 95% confidence interval [CI] 0.81–0.94) and the percent of vacant addresses in the neighborhood (OR 0.91, 95% CI 0.85–0.98). Patients living in such neighborhoods are less likely to be prescribed with newer ADD. There was no interaction between race-ethnicity and SDoH on the use of newer ADD. However, in the overall cohort, the non-Hispanic Black individuals were less likely to use newer ADD than the non-Hispanic White individuals (OR 0.82, 95% CI 0.76–0.88). Conclusion: Using a data-driven approach, we identified the key contextual-level SDoH factors associated with not following evidence-based treatment of T2D. Further investigations are needed to examine the mechanisms underlying these associations.
BibTeX
@article{li2023impact,
  author = {Yujia Li and Hui Hu and Yi Zheng and William T. Donahoo and Yi Guo and Jie Xu and Wei‐Han Chen and Ning Liu and Elisabeth A. Shenkman and Jiang Bian and Jingchuan Guo},
  title = {{Impact of Contextual-Level Social Determinants of Health on Newer Antidiabetic Drug Adoption in Patients with Type 2 Diabetes}},
  journal = {International Journal of Environmental Research and Public Health},
  year = {2023},
  doi = {10.3390/ijerph20054036},
}
Figure